CBD and gastric sleeve surgery is a combination that requires careful consideration before use. Gastric sleeve surgery permanently alters the stomach's anatomy, affecting how substances — including cannabidiol (CBD) — are absorbed and metabolised. CBD is a non-intoxicating compound derived from Cannabis sativa, widely available in the UK as a food supplement. However, its lipophilic nature, potential for drug interactions via the CYP450 enzyme system, and the altered pharmacokinetics following bariatric surgery mean that post-operative patients face unique risks. This article outlines what is currently known, the potential risks, and when to seek professional guidance.

How Gastric Sleeve Surgery Affects Drug Absorption

Gastric sleeve surgery reduces stomach volume by 75–80%, altering gastric pH, emptying time, and bile acid dynamics, which can affect absorption of lipophilic compounds such as CBD, though intestinal absorption pathways remain largely intact.

Sleeve gastrectomy, commonly known as gastric sleeve surgery, involves the surgical removal of approximately 75–80% of the stomach, leaving a narrow, tube-shaped pouch. This anatomical change has profound implications not only for food intake and weight loss, but also for how the body absorbs medications and supplements. Understanding these changes is essential before introducing any new substance — including cannabidiol (CBD) — into your post-operative routine.

Following gastric sleeve surgery, several pharmacokinetic factors are altered:

• Gastric volume and transit time are significantly reduced, meaning substances pass through the stomach more quickly

• Gastric acid production decreases, which can affect the dissolution of certain compounds

• Gastric pH rises, which may alter the solubility and early absorption of pH-sensitive drugs

It is important to note that, unlike gastric bypass, sleeve gastrectomy does not reroute the small intestine — the primary site of most oral drug absorption. Intestinal absorption pathways therefore remain largely intact. The principal pharmacokinetic effects arise from the altered gastric environment (reduced volume, higher pH, faster emptying) rather than from reduced intestinal surface area.

These changes can result in either reduced or, in some cases, enhanced absorption of certain drugs and supplements compared to pre-surgery levels. For lipophilic (fat-soluble) compounds in particular — a category that includes CBD — altered fat digestion and bile acid dynamics post-surgery may influence how much of the active compound reaches systemic circulation.

From a practical standpoint, bariatric guidelines (including those from the British Obesity and Metabolic Surgery Society, BOMSS) generally recommend preferring immediate-release or liquid formulations over modified-release or enteric-coated preparations in the early post-operative period, as the latter may not dissolve or be absorbed reliably in the altered gastric environment. Individual responses can vary considerably, and any changes to medication formulations should be discussed with your bariatric team or pharmacist.

Using CBD After Bariatric Surgery: What the Evidence Shows

No specific clinical guidelines from NICE, the NHS, or the MHRA address CBD use after bariatric surgery, and robust evidence confirming its safety or efficacy in gastric sleeve patients is currently lacking.

Cannabidiol (CBD) is a compound derived from the Cannabis sativa plant. Unlike tetrahydrocannabinol (THC), CBD is non-intoxicating and does not cause a high. It has attracted considerable public interest for its potential effects on pain, anxiety, sleep, and inflammation. However, when it comes to using CBD after bariatric surgery — including gastric sleeve procedures — the clinical evidence base remains limited, and no specific guidelines have been issued by NICE, the NHS, or the MHRA addressing this combination directly.

CBD is highly lipophilic, meaning it dissolves in fat rather than water. Its oral bioavailability in the general population is already considered relatively low — estimated at approximately 6–19% — largely due to extensive first-pass metabolism in the liver. Notably, taking CBD with a high-fat meal can substantially increase absorption. After gastric sleeve surgery, changes in gastric emptying, bile acid secretion, and fat absorption could theoretically alter this bioavailability further, though robust clinical studies in bariatric populations are currently lacking.

Some bariatric patients report using CBD to manage post-operative symptoms such as:

• Chronic pain or discomfort related to the surgery or underlying conditions

• Anxiety and low mood, which can be more prevalent in the post-operative period

• Sleep disturbances, which are common following significant dietary and lifestyle changes

Whilst anecdotal reports exist, there is currently no peer-reviewed clinical evidence confirming that CBD is either safe or effective for these purposes specifically in gastric sleeve patients. The absence of evidence is not the same as evidence of absence, but it does mean that caution and professional guidance are strongly advisable before use. Patients should not self-medicate with CBD as a substitute for evidence-based post-operative care.

For context, NICE guidance (NG144) on cannabis-based medicinal products covers licensed indications only (such as certain epilepsy syndromes, chemotherapy-induced nausea, and spasticity in multiple sclerosis) and does not endorse CBD food supplements for general wellness purposes.

Potential Risks and Drug Interactions to Be Aware Of

CBD inhibits CYP3A4 and CYP2C19 enzymes, raising the risk of interactions with warfarin, antiepileptics, immunosuppressants, and CNS depressants commonly prescribed after bariatric surgery.

One of the most clinically significant concerns surrounding CBD use after gastric sleeve surgery is its potential to interact with medications commonly prescribed in the post-operative period. CBD is metabolised primarily by the cytochrome P450 (CYP450) enzyme system in the liver — particularly CYP3A4 and CYP2C19. Many medications used by bariatric patients are processed by the same enzymes, creating a meaningful risk of drug–drug interactions.

Medications that may interact with CBD include:

• Anticoagulants such as warfarin — CBD may increase plasma levels, raising bleeding risk; INR should be monitored more closely if CBD is started or stopped

• Antiepileptic drugs such as clobazam — an interaction acknowledged in the SmPC for the licensed CBD medicine Epidyolex; CBD may also increase valproate-associated liver enzyme elevations, and liver function tests (LFTs) should be monitored accordingly

• Immunosuppressants such as tacrolimus, and certain antidepressants, which are metabolised via CYP3A4 or CYP2C19

• CNS depressants including opioids and benzodiazepines — additive sedation is possible; patients should avoid driving or operating machinery if they feel drowsy after taking CBD

Beyond drug interactions, CBD itself carries a recognised adverse effect profile. Reported side effects include fatigue, diarrhoea, changes in appetite, and elevated liver enzymes (hepatotoxicity), particularly at higher doses — as documented in the Epidyolex SmPC. For gastric sleeve patients who are already at risk of nutritional deficiencies and gastrointestinal sensitivity, these effects could be particularly problematic.

There is also the question of product quality and consistency. Unlike licensed medicines, most CBD products sold in the UK as food supplements are not subject to the same rigorous regulatory oversight, meaning actual CBD content and purity can vary significantly between products. The MHRA has taken enforcement action against some CBD products making unauthorised medicinal claims. The Food Standards Agency (FSA) advises that people who are pregnant, breastfeeding, trying to conceive, taking medicines, or who have liver disease should avoid CBD food supplements unless advised otherwise by a clinician. Post-bariatric surgery patients arguably fall within a similarly vulnerable category and should follow the same precautionary approach.

If you experience a suspected adverse reaction to a CBD product, you can report it to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk).

CBD Products Available in the UK and How They Are Taken

CBD is legally available in the UK as a food supplement; the FSA recommends a maximum of 10 mg per day for healthy adults and advises choosing products listed on its CBD novel foods public list.

In the UK, CBD products are legally available as food supplements provided they do not contain controlled cannabinoids (such as THC) above the legal limits set by the Home Office, and provided they do not make medicinal claims. Consumers should be aware that the legal threshold for controlled cannabinoids in finished consumer products is distinct from the cultivation thresholds applied to hemp crops; for accurate and up-to-date legal detail, refer to the Home Office drug licensing factsheet on cannabis and cannabinoids.

The FSA currently advises that healthy adults should consume no more than 10 mg of CBD per day from food supplement products. For post-operative bariatric patients, even this general guidance may not be appropriate without prior medical review. To reduce quality and safety risks, the FSA recommends choosing products that appear on its CBD public list (novel foods), which covers products that have submitted a valid novel food application.

Common CBD product formats include:

• CBD oils and tinctures — administered under the tongue (sublingually); some buccal absorption may occur, but a substantial proportion of the dose is swallowed and absorbed via the gastrointestinal tract. Systemic exposure remains variable, particularly after gastric sleeve surgery

• CBD capsules and softgels — swallowed and absorbed via the gastrointestinal system; absorption may be more unpredictable after gastric sleeve surgery, and modified-release or enteric-coated formulations are best avoided in the post-operative period

• CBD edibles (gummies, drinks) — subject to gastrointestinal absorption variability and often contain added sugars, which may be inappropriate following bariatric surgery

• CBD topicals (creams, balms) — applied to the skin; systemic absorption is minimal, making them a lower-risk option for localised discomfort, though evidence of efficacy is limited

It is worth noting that two cannabis-based medicines are currently licensed in the UK on prescription: Epidyolex (purified CBD, for specific epilepsy syndromes) and Sativex (a THC:CBD oromucosal spray, for spasticity in multiple sclerosis). Neither is relevant to general wellness use, and both are distinct from over-the-counter CBD food supplements.

When to Seek Advice From Your Bariatric or Medical Team

Patients should consult their bariatric surgeon, GP, or specialist nurse before using CBD post-operatively, particularly if taking prescribed medications, as interactions and altered absorption pose clinically important risks.

If you are considering using CBD following gastric sleeve surgery, the most important first step is to discuss this with your bariatric surgeon, specialist nurse, or GP before starting. This is not merely a precaution — it is a clinically important step given the potential for drug interactions, altered absorption, and the complexity of post-operative nutritional management.

Worried about interactions with other medications? Speak to one of our pharmacists →

You should seek prompt advice from your medical team if:

• You are currently taking any prescribed medication, particularly anticoagulants (e.g., warfarin — agree INR monitoring), antidepressants, antiepileptics (e.g., clobazam or valproate — agree LFT monitoring), immunosuppressants (e.g., tacrolimus), or CNS depressants

• You experience new or worsening gastrointestinal symptoms after starting CBD, such as diarrhoea, nausea, or abdominal pain

• You notice unexpected changes in the effects of your regular medications, which could suggest a pharmacokinetic interaction

• You develop signs of liver dysfunction, including jaundice, dark urine, or persistent fatigue, as CBD has been associated with elevated liver enzymes at higher doses

• You are experiencing significant mood changes, anxiety, or pain post-operatively — these symptoms warrant proper clinical assessment rather than self-management with supplements

• You feel drowsy or sedated after taking CBD, in which case you should not drive or operate machinery until the effect has resolved

Your bariatric team is best placed to review your full medication list, assess your nutritional status, and advise on whether CBD use is appropriate in your individual circumstances. If CBD is deemed suitable, they may recommend starting at the lowest possible dose and monitoring closely for any changes.

Your community pharmacist can also review your medicines and flag potential interactions — this is a valuable, accessible resource. If you experience a suspected adverse reaction to a CBD product or to any medicine, please report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Ultimately, whilst CBD is widely available and generally perceived as a natural product, 'natural' does not mean risk-free — particularly in the context of post-bariatric surgery care.

Frequently Asked Questions